SNSE Jefferies Global Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning again, everybody, and welcome to the Jefferies 2026 Global Healthcare Conference. It is my pleasure to now introduce you, Anand Parikh, the CEO of Faeth Therapeutics. Just a reminder that the meeting will be 20 minutes and with five minutes Q&A.
Thank you. Hi there. I'm Anand Parikh, CEO of Faeth Therapeutics.
This presentation may contain forward-looking statements. Please refer to our 10-K for all appropriate risk factors. Faeth's a company focused on multi-node inhibition of crucial cancer pathways. We are beginning with the PI3K/AKT/mTOR pathway, which my co-founder, Lew Cantley, discovered. We have two oral small molecules which inhibit PI3K-alpha and mTORC1 and two. Our molecules, we believe, confer a unique PK advantage, which allows us to see lower stomatitis and better target coverage than other multi-node inhibitors in the space. We are developing these assets in endometrial cancer and in breast cancer. We went public earlier this year with $200 million raised.
As of the end of Q3, we have $176 million in cash, and that funds us through several major catalysts, including maturation of our recently announced phase II endometrial data and breast cancer data as well at year-end next year. As I mentioned, my co-founders include Dr. Lewis Cantley, who discovered the PI3K/AKT/mTOR pathway, and our molecules were designed by Kevan Shokat, who is one of the world's leading medicinal chemists. Serabelisib, as I mentioned, it hits PI3K-alpha at the top of the pathway, and sapanisertib, mTORC1/2 at the bottom of the pathway. So we really have a vertical clamp on this pathway. One of the key challenges with this pathway has been tolerability. What we see is that multi-node inhibitors are actually able to dose much lower than their single-node counterparts.
Single-node inhibitors, even our own molecules, when developed as monotherapy or in combination with other agents, are dosed at a very high level. You can see here through the lens of our own molecules, serabelisib at monotherapy doses was 900 milligrams. When dosed in combination, it's dosed at 200 milligrams. This is four and a half fold lower. Similar story for sapanisertib. When you look at some of our clinical data, you may say, "Wow, how do you see such low hyperglycemia and stomatitis?" This is part of the reason. This is really the crux of the biology and why we can shut down the pathway better than single-node inhibitors. Taking you back to your PhD program here with some Western blots.
But what we see is that single-node inhibitors, either the approved inhibitors on the left of the slide or investigational agents on the right of the slide, can shut down phosphorylation of S6, which is the translational readout at the bottom of the pathway, but it cannot shut down phosphorylation of 4EBP1, which is the other readout at the bottom of the pathway. S6 relates to cell size, 4EBP1 to potency. You can see that our molecules, when dosed together, do indeed shut down the pathway. Another molecule that shuts down the pathway in a similar fashion is gedatolisib, the recently approved molecule developed by Celcuity. It's an intravenous drug dosed once weekly, three weeks a month. We are, of course, oral, dosed three days on, four days off.
The difference you see confers not only a route of administration benefit and a convenience benefit, but it also confers this unique PK benefit, where we do not have such a high Cmax, but we have greater target coverage for longer. On any given week, two to 3x gedatolisib's target coverage. We believe that this avoids the stomatitis, which we now have clinical proof for, but also gives us greater durability of target coverage. This is kind of how we stack up. For reasons I've explained, we believe that multi-node inhibition of the pathway is biologically superior to single node. But multi-node inhibition, if done incorrectly, can cause a lot of toxicity. We believe that we kind of hit that Goldilocks zone where we're oral, we're multi-node, and now with our phase II data in endometrial cancer, we can see the toxicity benefit.
Let's move on to that data. When speaking about endometrial cancer, a lot of people see ADCs in development, but what they don't realize is that really the only other mechanism of action beyond a topo 1 ADC is Faeth. I think we're the only agent post phase I-B really in this space. All of the ADCs are topo one ADCs. They cannot be sequenced one after another. What do I mean by that? Once you get one topo 1 ADC, that is likely the only topo 1 ADC you are going to receive. All of these people in the ADC bucket are fighting for a fixed patient population. Whether we treat patients before an ADC or after an ADC, we will see all of these patients. We believe that our TAM, just in the U.S., in endometrial cancer, is about $2.5 billion.
Here's the setup for our clinical trial data, which we presented earlier this month. We treated patients with endometrioid endometrial cancer, second line or later, post-IO, post-carboplatin. This is one of the most heavily pre-treated populations ever shown in an endometrial cancer dataset post-phase II. We estimate that about 40% of these patients would have been ineligible for the TroFuse study. So TroFuse-005, the recent Merck study, about 40% of our patients, either dint of prior lines of study or baseline characteristics in terms of neuropathy, prior cancer treatment, et cetera, would have been ineligible for TroFuse. When we look at this study, despite such a heavily pre-treated population, we still saw an overall response rate of 33%, 12 out of 36 patients, with a clearly right-shifted waterfall plot.
The black diamonds denote patients that are still on study. You can see there are a number of patients still on study with the opportunity for their responses to deepen even further. When we look at patients cut by PIK3CA mutation or not, which we think confers a lot of translational capacity to breast, where PIK3CA mutations are even more prevalent, and remember, these are on the background of 80% of these patients having PTEN loss, we are seeing really nice response rates across both PIK3CA mutated and not. We think this, again, translates very nicely to breast cancer. You can see that the responses were durable for many of these patients, and that these patients are pretty sick. You can see death in some of these patients even before receiving a meaningful amount of drug.
Again, when we look at the tumor shrinkage, we can see that most of these patients are below the line, indicating significant tumor shrinkage, and that responses deepen over time. We see responses not only at the first scan, but at second scan, third scan, and even a patient here, the furthest along patient, who has been on trial for 20 months when they had a response. When we look at the preliminary PFS, we see a very nice curve here, where we see a median PFS of 7.4 months, and PFS6 of 62%. This compares quite nicely to sacituzumab govitecan, and this is in the ITT population. If we look then at the efficacy evaluable population, that number increases even further. This is very competitive with many of the other agents in the space, which I will get into.
I think the other thing that is exciting about this study is the safety profile and how it translates to breast. 26% of patients had neutropenia that is attributable to the paclitaxel, and we have no prophylactic for neutropenia, unlike many of the other ADCs. We will likely introduce prophylactic for paclitaxel in the phase III. That neutropenia was all lab values, no febrile neutropenia, and then only two of 42 patients discontinued due to treatment-related adverse events. There were no drug-related deaths, despite the heavily pre-treated nature of this population. Diving into the adverse events that are looking across, you can see that the PAM-related adverse events, which we will dive into detail on the next couple of slides, were low. Nausea, vomiting, and diarrhea, which are paclitaxel signatures, were in line with what is seen for other agents in this drug class.
As we move on to breast cancer, where the combination partners will be our recently announced collaboration with Roche, giredestrant, fulvestrant, and CDK, we anticipate that nausea, vomiting, and diarrhea will be greatly decreased. As we look at hyperglycemia, you can see that despite enrolling a baseline patient population that is half diabetic or pre-diabetic, and having an HbA1c criteria of eight, we still have best-in-class hyperglycemia, with very low grade 3. We think this augurs very well for breast, again, where we have a patient population that is estimated to be about 10% diabetic, 25% either diabetic or pre-diabetic. Stomatitis, I mentioned gedatolisib had very high rates of stomatitis, even with a prophylaxis. We have no prophylaxis, and we had low rates of stomatitis. Again, important to note here that paclitaxel itself does have some stomatitis.
We believe that in breast, these rates will be even lower, again, on the background of no prophylaxis. As we look at the ORR and the PFS across what would be the likely comparator in a phase III, which is paclitaxel, we will have an announcement on that in Q1. We think we compare quite nicely to paclitaxel alone in less heavily pre-treated patient populations. Again, this is paclitaxel data in an IO-naive population in the HAN study, or in an earlier line population in the TROPHY study. You can see quite nice benefit here. When we compare to phase II studies of various ADCs, and remember, we can be sequenced before or after any of these ADCs, we still believe that our data is quite competitive with many of the other agents in phase II.
We are excited about this opportunity in endometrial cancer and to bring something to patients that is not a TOP1 ADC. Again, you can also see, despite small Ns, that it is quite competitive with trastuzumab deruxtecan in endometrial cancer, in treatment-naive patients as well. Breast cancer, which is obviously a much larger market, we can treat 100% of patients across breast cancer. Unlike single-node inhibitors, we are not limited to a particular mutational subset. We will enroll patients with both PIK3CA mutations and patients without, PIK3CA wild-type patients. It is a large market. I probably do not need to tell many of you that. We have generated data already in breast cancer when these agents were in Celcuity's hands. Sapanisertib plus fulvestrant was randomized against fulvestrant alone, and you can see benefit derived here that was across patients who were both mutated and wild-type for the pathway.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
